Increase in plasma HDL-cholesterol in hypertensive patients treated with enalapril.
The effects of enalapril on plasma lipoproteins were evaluated in an open study of 12 normolipidemic outpatients with mild-to-moderate essential hypertension (World Health Organization stages I and II). After a two-week washout period, during which placebo was given, the patients received 20 to 40 mg/day of enalapril for 16 weeks. Treatment with enalapril was associated with significant increases in levels of HDL cholesterol (mean, 23%; P less than 0.001) and apoprotein A (mean, 11%; P less than 0.01), largely because of the increase in the subfraction HDL2 (mean, 43%; P less than 0.001), although the subfraction HDL3 also rose (mean, 14%; P less than 0.005). Total cholesterol and LDL cholesterol levels did not change, whereas triglycerides decreased significantly (mean, 26%; P less than 0.001). Apoprotein B was unchanged. Unlike diuretics and most beta-blockers, enalapril favorably affects plasma lipoprotein levels, thus improving the overall cardiovascular risk in hypertensive patients.
Perani
G
G
Department of Internal Medicine, University of Pavia, Italy.
Muggia
C
C
Martignoni
A
A
Bongarzoni
A
A
Radaelli
A
A
Testa
F
F
Finardi
G
G
D000328:Adult; D001054:Apolipoproteins A / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D004656:Enalapril / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged
D001054:Apolipoproteins A; D008076:Cholesterol, HDL; D004656:Enalapril